Systemic Lupus Erythematosus (SLE) is a complex, multifaceted disease that poses significant challenges with regards to diagnosis, treatment, monitoring of disease status, prevention and management of accruing complications and comorbidities. Nonetheless, during the past years, substantial progress has been made due to high-quality clinical studies which have enlightened several aspects in the disease management. This has been paralleled by the successful completion of a number of randomized controlled trials (RCTs) demonstrating superiority of novel compounds against conventional agents. Importantly, the introduction of biological treatments in SLE has paved the way for a true paradigm shift in the care of these patients as they enable reduction of glucocorticoids use, better disease control targeting at ambitious -yet feasible-treatment goals, and improvement in the natural history and prognosis of the disease due to reduced comorbidities and end-organ damage and improved health-related quality of life. In this review, we focus on four critical aspects in the contemporary management of SLE including early disease diagnosis, evidence-based strategies for glucocorticoids tapering and prevention flares, and finally, the emerging role of non-immunosuppressive adjunct therapies to facilitate damage-free prognosis.